CUPERTINO, Calif., Nov. 15, 2019 /PRNewswire/ -- DURECT
Corporation (Nasdaq: DRRX) announced today that James E. Brown, President and CEO, will be
presenting at the Stifel 2019 Health Care Conference, at the Lotte
New York Palace Hotel on Tuesday,
November 19, 2019 at 3:35 p.m.
EST. Institutional investors and analysts that are
attending the conference may request a one-on-one meeting through
the conference coordinators.
A live audio webcast of the presentation will be available by
accessing http://wsw.com/webcast/stifel18/drrx/
The live audio webcast of the presentation will also be
available by accessing DURECT's homepage at www.durect.com and
clicking on the "Investors" tab. If you are unable to
participate during the live webcast, the call will be archived on
DURECT's website in the "Event Calendar" of the "Investors"
section.
About DURECT Corporation
DURECT is a biopharmaceutical company actively developing
therapeutics based on its Epigenetic Regulator Program and
proprietary drug delivery platforms. DUR‑928, a new chemical
entity in Phase 2 development, is the lead candidate in DURECT's
Epigenetic Regulator Program. An endogenous, orally
bioavailable small molecule, DUR-928 has been shown in preclinical
studies to play an important regulatory role in lipid homeostasis,
inflammation, and cell survival. Human applications may
include acute organ injury such as AH and acute kidney injury
(AKI), chronic hepatic diseases such as NASH, and inflammatory skin
conditions such as psoriasis and atopic dermatitis. DURECT's
advanced oral and injectable delivery technologies are designed to
enable new indications and enhanced attributes for small-molecule
and biologic drugs. Key product candidates in this category
include POSIMIR® (bupivacaine extended-release
solution), an investigational locally-acting, non-opioid analgesic
intended to provide up to 3 days of continuous pain relief after
surgery, and a long-acting injectable SABER-based HIV
investigational product being developed with Gilead. For more
information about DURECT, please visit www.durect.com.
DURECT Forward-Looking Statement
The statements in this press release regarding the potential
benefits and uses of DUR-928 to treat AH and about other potential
uses of DUR-928 to treat renal diseases, such as NASH and AKI, and
inflammatory skin conditions such as psoriasis and atopic
dermatitis, the potential use of POSIMIR to treat post-operative
pain, and the potential development of a long-acting injectable
SABER-based HIV product with Gilead are forward-looking statements
involving risks and uncertainties that can cause actual results to
differ materially from those in such forward-looking statements.
Potential risks and uncertainties include, but are not
limited to, the risk of delays in clinical trials or adverse safety
events from patients administered with DUR-928, the risk that the
ongoing clinical trials of DUR-928 in NASH or psoriasis do not
successfully achieve their endpoints, the risk that placebo
controlled studies of DUR-928 required for regulatory approval will
not replicate results from open label clinical trials or trials
with small numbers of patients or historical controls, the risks
that the long-acting injectable SABER-based HIV investigational
product being developed with Gilead will not succeed or that Gilead
will abandon this program, the risk that the FDA Advisory Committee
will not recommend approval of POSIMIR or that the FDA will not
approve POSIMIR, and the risk of delays and costs due to additional
work or other requirements imposed by regulatory agencies for
continued development, approval or sale of any of our product
candidates. Further information regarding these and other
risks related to DURECT is included in DURECT's Form 10-Q filed on
November 5, 2019 under the heading
"Risk Factors" and in subsequent reports that we file with the
Securities and Exchange Commission.
NOTE: POSIMIR® and SABER® are trademarks
of DURECT Corporation. Other referenced trademarks belong to
their respective owners. DUR-928 and POSIMIR are drug
candidates under development and have not been approved for
commercialization by the U.S. Food and Drug Administration or other
health authorities.
View original
content:http://www.prnewswire.com/news-releases/durect-to-present-at-the-stifel-2019-health-care-conference-300959006.html
SOURCE DURECT Corporation